AU2019240247B2 - Fc variant compositions and methods of use thereof - Google Patents
Fc variant compositions and methods of use thereofInfo
- Publication number
- AU2019240247B2 AU2019240247B2 AU2019240247A AU2019240247A AU2019240247B2 AU 2019240247 B2 AU2019240247 B2 AU 2019240247B2 AU 2019240247 A AU2019240247 A AU 2019240247A AU 2019240247 A AU2019240247 A AU 2019240247A AU 2019240247 B2 AU2019240247 B2 AU 2019240247B2
- Authority
- AU
- Australia
- Prior art keywords
- antibody
- amino acid
- polypeptide
- seq
- region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Life Sciences & Earth Sciences (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2026203163A AU2026203163A1 (en) | 2018-03-21 | 2026-04-28 | Fc variant compositions and methods of use thereof |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862646053P | 2018-03-21 | 2018-03-21 | |
| US62/646,053 | 2018-03-21 | ||
| PCT/US2019/023382 WO2019183362A1 (en) | 2018-03-21 | 2019-03-21 | Fc variant compositions and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2026203163A Division AU2026203163A1 (en) | 2018-03-21 | 2026-04-28 | Fc variant compositions and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2019240247A1 AU2019240247A1 (en) | 2020-10-15 |
| AU2019240247B2 true AU2019240247B2 (en) | 2026-01-29 |
Family
ID=67988040
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2019240247A Active AU2019240247B2 (en) | 2018-03-21 | 2019-03-21 | Fc variant compositions and methods of use thereof |
| AU2026203163A Pending AU2026203163A1 (en) | 2018-03-21 | 2026-04-28 | Fc variant compositions and methods of use thereof |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2026203163A Pending AU2026203163A1 (en) | 2018-03-21 | 2026-04-28 | Fc variant compositions and methods of use thereof |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US20210070860A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3768315A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7551499B2 (cg-RX-API-DMAC7.html) |
| AU (2) | AU2019240247B2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019183362A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6932700B2 (ja) * | 2015-09-15 | 2021-09-08 | アムジエン・インコーポレーテツド | 4価の二重特異性抗原結合タンパク質及び4価の四重特異性抗原結合タンパク質、ならびにそれらの使用 |
| TWI869528B (zh) | 2020-01-13 | 2025-01-11 | 美商威特拉公司 | C5ar1抗體分子及其用途 |
| US11912781B2 (en) | 2021-01-13 | 2024-02-27 | Visterra, Inc. | Humanized complement 5A receptor 1 antibodies and methods of use thereof |
| CN113061192B (zh) * | 2021-04-12 | 2023-08-22 | 佰思巢(上海)生物科技有限公司 | 一类对pd-1受体具有高亲和力的pdl1融合蛋白及其作为t细胞抑制剂的应用 |
| CN115873126A (zh) * | 2021-11-26 | 2023-03-31 | 深圳科兴药业有限公司 | 人生长激素融合蛋白及其制备和用途 |
| CA3263665A1 (en) | 2022-08-15 | 2024-02-22 | Dana-Farber Cancer Institute, Inc. | Anti-CLDN4 antibodies and their methods of use |
| WO2024039672A2 (en) | 2022-08-15 | 2024-02-22 | Dana-Farber Cancer Institute, Inc. | Antibodies against msln and methods of use thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013165690A1 (en) * | 2012-04-30 | 2013-11-07 | Medimmune, Llc | Molecules with reduced effector function and extended half-lives, compositions, and uses thereof |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP0104865A3 (en) | 1999-01-15 | 2004-07-28 | Genentech Inc | Polypeptide variants with altered effector function |
| CN102549016B (zh) * | 2009-06-30 | 2015-05-06 | 研究发展基金会 | 免疫球蛋白fc多肽 |
| ES2573642T3 (es) * | 2009-12-23 | 2016-06-09 | Synimmune Gmbh | Anticuerpos anti-FLT3 y métodos de usar los mismos |
| CA2826467C (en) * | 2011-02-07 | 2019-11-12 | Research Development Foundation | Engineered immunoglobulin fc polypeptides |
| US9028826B2 (en) | 2011-04-04 | 2015-05-12 | The Trustees Of Dartmouth College | Methods of immune therapy with anti-CD154 antibodies having impaired FcR binding and/or complement binding properties |
| WO2013002362A1 (ja) * | 2011-06-30 | 2013-01-03 | 中外製薬株式会社 | ヘテロ二量化ポリペプチド |
| WO2014006217A1 (en) * | 2012-07-06 | 2014-01-09 | Genmab B.V. | Dimeric protein with triple mutations |
| WO2016033509A1 (en) | 2014-08-29 | 2016-03-03 | The Regents Of The University Of Colorado, A Body Corporate | Aquaporin-4 antibodies and uses thereof for the treatment of neuromyelitis optica |
| US20170362324A1 (en) * | 2014-09-12 | 2017-12-21 | Biogen Ma Inc. | Humanized anti-alpha v beta 5 antibodies and uses thereof |
| EP3250602A1 (en) * | 2015-01-26 | 2017-12-06 | Cellectis | T cell receptor knock out engineered immune cells, endowed with chimeric antigen receptors binding to cd123 for the treatment of relapsed/refractory acute myeloid lymphoma or blastic plasmacytoid dendritic cell neoplasm |
| CA2978501A1 (en) | 2015-03-05 | 2016-09-09 | Ucb Biopharma Sprl | Polymeric fc proteins and methods of screening to alter their functional characteristics |
| MX2017012805A (es) * | 2015-04-07 | 2018-04-11 | Genentech Inc | Complejo de unión a antígenos con actividad agonista y métodos de uso. |
| CA3031194A1 (en) * | 2016-07-22 | 2018-01-25 | Dana-Farber Cancer Institute, Inc. | Glucocorticoid-induced tumor necrosis factor receptor (gitr) antibodies and methods of use thereof |
| EP3494139B1 (en) * | 2016-08-05 | 2022-01-12 | F. Hoffmann-La Roche AG | Multivalent and multiepitopic anitibodies having agonistic activity and methods of use |
-
2019
- 2019-03-21 WO PCT/US2019/023382 patent/WO2019183362A1/en not_active Ceased
- 2019-03-21 EP EP19771823.2A patent/EP3768315A4/en active Pending
- 2019-03-21 US US16/982,723 patent/US20210070860A1/en active Pending
- 2019-03-21 AU AU2019240247A patent/AU2019240247B2/en active Active
- 2019-03-21 JP JP2020550791A patent/JP7551499B2/ja active Active
-
2024
- 2024-02-06 US US18/434,536 patent/US20250066481A1/en active Pending
- 2024-03-26 JP JP2024049655A patent/JP7804715B2/ja active Active
-
2026
- 2026-04-28 AU AU2026203163A patent/AU2026203163A1/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013165690A1 (en) * | 2012-04-30 | 2013-11-07 | Medimmune, Llc | Molecules with reduced effector function and extended half-lives, compositions, and uses thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| US20210070860A1 (en) | 2021-03-11 |
| AU2026203163A1 (en) | 2026-05-14 |
| JP2024081718A (ja) | 2024-06-18 |
| EP3768315A1 (en) | 2021-01-27 |
| AU2019240247A1 (en) | 2020-10-15 |
| JP7804715B2 (ja) | 2026-01-22 |
| JP2021518411A (ja) | 2021-08-02 |
| EP3768315A4 (en) | 2022-11-30 |
| US20250066481A1 (en) | 2025-02-27 |
| JP7551499B2 (ja) | 2024-09-17 |
| WO2019183362A1 (en) | 2019-09-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240336694A1 (en) | Compositions and methods for augmenting antibody mediated receptor signaling | |
| US20250066481A1 (en) | Fc variant compositions and methods of use thereof | |
| US20230227584A1 (en) | Bispecific antibodies comprising a modified c-terminal crossfab fragment | |
| CN113614109A (zh) | 双功能抗pd-1/il-7分子 | |
| CN112119099A (zh) | 三特异性抗原结合蛋白 | |
| KR20250137191A (ko) | D-도메인 함유 폴리펩타이드 및 이의 용도 | |
| JP2022504826A (ja) | 4-1bb及び腫瘍関連抗原に結合する抗体構築物ならびにその使用 | |
| TW201522373A (zh) | 抗cd52之抗體 | |
| KR20230018425A (ko) | 항-cd200r1 항체 및 이의 사용 방법 | |
| KR20250129817A (ko) | D-도메인 함유 폴리펩티드 및 그의 용도 | |
| JP2025525886A (ja) | Cd28に対する多機能性分子 | |
| EP3559033A1 (en) | Humanized cxcr3 antibodies with depleting activity and methods of use thereof | |
| WO2023138638A1 (zh) | 抗tigit和pd-l1的双特异性抗原结合蛋白及其用途 | |
| KR20240116828A (ko) | 이중 mhc-표적화 t 세포 관여자 | |
| WO2025072871A2 (en) | ANTI-SIRPα ANTIBODY COMPOSITIONS AND USES THEREOF | |
| WO2025049915A1 (en) | Ilt2 binding agents and uses thereof | |
| CN121219321A (zh) | 与bcma特异性结合的免疫刺激性抗原结合分子 | |
| HK40114235A (en) | Agonistic ltbr antibodies and bispecific antibodies comprising them | |
| HK40114510A (en) | Agonistic ltbr antibodies and bispecific antibodies comprising them | |
| TW202509064A (zh) | 靶向干擾素α融合蛋白及使用方法 | |
| CN118434768A (zh) | 激动性ltbr抗体以及包含它们的双特异性抗体 | |
| TW202602924A (zh) | 抗ccr8抗體之醫藥配製物 | |
| HK40075193A (en) | Bispecific antibodies comprising a modified c-terminal crossfab fragment | |
| WO2022098910A1 (en) | Icos antibodies for treatment of lymphomas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |